Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Beigene Ltd (BGNE)  
$241.20 13.29 (5.22%) as of 4:30 Fri 6/27


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 90,630,000
Market Cap: 21.86(B)
Last Volume: 0 Avg Vol: 0
52 Week Range: $142.67 - $278.38
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:

   

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   BeiGene is a commercial-stage biotechnology company focused on developing and commercializing molecularly-targeted and immuno-oncology cancer therapeutics. Co.'s clinical-stage drug candidates include: Zanubrutinib, which is a small molecule inhibitor of Bruton's tyrosine kinase for the treatment of mantle cell lymphoma in adult patients; Tislelizumab, which is a humanized monoclonal antibody against the immune checkpoint receptor programmed cell death protein 1; Pamiparib (BGB-290), which is for the treatment of various solid tumors; and Lifirafenib, which is an investigational small molecule inhibitor with RAF monomer and dimer inhibition activities.


 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 203,452 1,421,863 20,425,867 21,641,969
Total Sell Value $51,856,153 $359,832,086 $2,147,483,647 $2,147,483,647
Total People Sold 6 7 9 10
Total Sell Transactions 20 37 53 73
End Date 2025-03-30 2024-12-27 2024-06-28 2023-06-29

   
Records found: 654
  Page 1 of 27  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Wang Xiaodong Chair, Scientific Advisory Brd   –       •      –    2025-06-24 4 AS $263.50 $532,867 D/D (2,007) 0 -10%     
   Wu Xiaobin President and COO   •       –      –    2025-06-23 4 S $260.00 $354,380 D/D (1,363) 0 6%     
   Wang Lai Global Head of R&D   •       –      –    2025-06-23 4 S $260.00 $267,280 D/D (1,028) 0 6%     
   Oyler John Chief Executive Officer   •       •      –    2025-06-23 4 S $261.57 $830,360 D/D (3,174) 0 6%     
   Oyler John Chief Executive Officer   •       •      –    2025-06-17 4 S $256.49 $374,473 D/D (1,460) 0 5%     
   Wang Lai Global Head of R&D   •       –      –    2025-06-17 4 S $251.37 $118,142 D/D (470) 0 5%     
   Wu Xiaobin President and COO   •       –      –    2025-06-17 4 S $250.87 $158,047 D/D (630) 0 5%     
   Oyler John Chief Executive Officer   •       •      –    2025-06-16 4 S $266.05 $979,046 D/D (3,680) 1,460 9%     
   Wang Lai Global Head of R&D   •       –      –    2025-06-16 4 S $266.40 $313,558 D/D (1,177) 470 9%     
   Lee Chan Henry SVP, General Counsel   •       –      –    2025-06-16 4 S $266.50 $112,463 D/D (422) 0 9%     
   Wu Xiaobin President and COO   •       –      –    2025-06-16 4 S $265.47 $409,694 D/D (1,543) 630 9%     
   Ball Titus B. Principal Accounting Officer   •       –      –    2025-06-11 4 S $258.36 $34,620 D/D (134) 0 8%     
   Wang Lai Global Head of R&D   •       –      –    2025-06-10 4 A $0.00 $0 D/D 86,359 1,058,304     -
   Lee Chan Henry SVP, General Counsel   •       –      –    2025-06-10 4 A $0.00 $0 D/D 46,878 283,920     -
   Oyler John Chief Executive Officer   •       •      –    2025-06-10 4 A $0.00 $0 D/D 185,055 8,281,841     -
   Ball Titus B. Principal Accounting Officer   •       –      –    2025-06-10 4 A $0.00 $0 D/D 29,601 73,983     -
   Rosenberg Aaron Chief Financial Officer   •       –      –    2025-06-10 4 A $0.00 $0 D/D 63,674 230,802     -
   Wang Xiaodong Chair, Scientific Advisory Brd   –       •      –    2025-06-10 4 AS $261.20 $10,975,316 D/D (41,760) 0 -8%     
   Wang Xiaodong Chair, Scientific Advisory Brd   –       •      –    2025-06-10 4 OE $6.50 $271,440 D/D 41,760 41,760     -
   Wang Xiaodong Chair, Scientific Advisory Brd   –       •      –    2025-06-10 4 A $0.00 $0 D/D 98,696 5,180,861     -
   Yi Qingqing Director   –       •      –    2025-06-10 4 D $0.00 $0 D/D (29,614) 27,326     -
   Wu Xiaobin President and COO   •       –      –    2025-06-10 4 A $0.00 $0 D/D 123,370 1,274,296     -
   Wu Xiaobin President and COO   •       –      –    2025-06-06 4 S $250.74 $489,591 D/D (1,934) 0 6%     
   Oyler John Chief Executive Officer   •       •      –    2025-06-06 4 S $250.84 $1,295,946 D/D (5,127) 0 6%     
   Lee Chan Henry SVP, General Counsel   •       –      –    2025-06-06 4 S $255.78 $179,280 D/D (700) 0 6%     

  654 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 27
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed